Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Alshiekh-Nasany R et al
Understanding your personal timeline helps set realistic expectations and stay motivated during treatment
Timeline patterns (not guarantees): Ivim Health does not publish a specific week-by-week guaranteed timeline on their product page
Contact an Interstate Health location near you to get started today
Conclusions This analysis demonstrates that semaglutide 2.4 mg represents a cost-effective intervention for obese patients with MASH (F3) without diabetes within the Italian healthcare setting, generating substantial health gains and remaining below the commonly accepted willingness-to-pay threshold, reporting an ICER equal to 22,691 per QALY gained for the basecase scenario
Most state Medicaid programs cover GLP-1 medications when prescribed for Type 2 diabetes, but coverage for obesity or weight loss is far less consistent
US$ 28.52
US$ 22.28
US$ 29.76
